Raloxifene binds to estrogen receptors, exerting estrogenic effects on bone and lipid metabolism while having anti-estrogenic effects on breast and uterine tissues. This selective action helps in increasing bone mineral density, thereby reducing the risk of fractures, and lowering the risk of breast cancer by inhibiting estrogen-stimulated growth of breast tissue.
